



ASPIrin in Reducing Events in the Elderly

ASPREE

Aspirin in Reducing Events in the Elderly



& Collaborators



ASPREE STUDY FEATURES

- **Focused entirely on people aged over 70 years.**
- **Looking at an outcome that matters**
 - **to prolong a high quality of disability-free life**
- **International study funded by the peak medical research organisations in Australia (NHMRC, CSIRO) and the USA (NIH).**
- **Collaboration between Universities, GPs, Government and the community**
- **Largest primary prevention trial ever undertaken in Australia**





Why the emphasis on the over 70's?



- People over 70 are under-represented in clinical studies.
- Results from trials in other age groups are extrapolated to older people;
 - Yet older people receive most medical treatments.
- Lifespan and demographic changes in western world → ageing population

STUDY BASICS


- Daily low -dose aspirin (100mg enteric-coated) *or* placebo
- 19,000 participants (12,500 AUS; 6,500 USA)
- Aged 70 plus, able-bodied
- Follow-up 5 years





ASPIrin in Reducing Events in the Elderly

**To be involved in the study, speak with me
after or call 1800 728 745.**



Website: www.aspree.org

